Difference between revisions of "Forodesine (Fodosine)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) |
||
| Line 20: | Line 20: | ||
[[Category:PMDA approved in 2017]] | [[Category:PMDA approved in 2017]] | ||
| − | |||
Revision as of 01:02, 15 June 2023
Mechanism of action
From the NCI Drug Dictionary: The hydrochloride salt of the synthetic high-affinity transition-state analogue forodesine. Forodesine binds preferentially to and inhibits purine nucleotide phosphorylase (PNP), resulting in the accumulation of deoxyguanosine triphosphate and the subsequent inhibition of the enzyme ribonucleoside diphosphate reductase and DNA synthesis. This agent selectively causes apoptosis in stimulated or malignant T-lymphocytes.
Diseases for which it is used
History of changes in PMDA indication
- 2017-03-30: Initial approval for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Also known as
- Code name: BCX-1777
- Generic name: immucillin H
- Brand name: Fodosine, Mundesine